Subject: Fwd: Confidential Portfolio Company Update
From: "William Lee" <[email-masked]>
To: "Smith, Brien" <[email-masked]>
Cc: "Paul Daggett" <[email-masked]>, "Doug Manor" <[email-masked]>, "Tutrone, Anthony" <[email-masked]>, <[email-masked]>, "Shofet, Jonathan" <[email-masked]>, <[email-masked]>, "John DeLoche" <[email-masked]>, "Neil Callahan" <[email-masked]>, "Devon Archer" <[email-masked]>, "Hunter Biden" <[email-masked]>
Date: Sun, 1 Jun 2014 14:58:06 -0700

Hi Brien,

Hope you are having a great weekend.  I wanted to make sure you and your investment committee have this RSTP internal portfolio update given the recent positive momentum from Counsyl.

I would also like to confirm our call on Tuesday at 11:30AM Pacific.  The dial-in number is: 202.446.0487, 333188#.

Best regards,
Will

Begin forwarded message:

> From: John DeLoche <[email-masked]>
> Subject: Confidential Portfolio Company Update
> Date: June 1, 2014 at 12:20:24 PM PDT
> To: William Lee <[email-masked]>, Neil Callahan <[email-masked]>, Devon Archer <[email-masked]>, Hunter Biden <[email-masked]>, Rob Walker <[email-masked]>, Eric Schwerin <[email-masked]>
> 
> Team,
> 
> A few updates from this weekend and for planning this coming week on Counsyl:
> 
> 1. UHC: While interviewing CFO candidates at the company over the weekend, managment gave us the update that our introduction to United Healthcare appears to be paying off. Confidentially, Counsyl has received an in-network agreement with UHC that they expect will be executed this week. With UHC, Counsyl will have in-network status at all major insurers in the US which is a huge milestone for the company, bringing them to 160mm in network covered lives. Please treat with highest confidentiality as this has not been announced. 
> 
> 2. NIPT test introduction: Counsyl will have its third test, NIPT (non-invasive prenatal test for down syndrome, an amniocentesis replacement) in the market by Q3, 2014, earlier than planned. This will be brought to market through a partnership with Illumina, which is one of Counsyl's strategic investors. The introduction of this test earlier than planned has significant positive implications for 2014 financial performance. There will likely be a press release to announce this in Q3. 
> 
> 3. Strategic Marketing: RSTP will provide introductions for Counsyl to the Susan Komen Foundation and Brightpink.com. We have a call with the company on 6/2 with Ramji and team discuss specifics and a roadmap for partnering with each organization. A partnership with one of both of these organizations can provide a specific call to action and drive brand awareness and sales volume.
> 
> 4. China: We have a call scheduled with Counsyl on 6/5 including our Business Development Team and Shirley Young. Shirley brought GM into China and is under consideration as an outside board member. We will discuss the regulatory and tactical roadmap for entering China. We will also cover potential strategic partners and investors who we believe could be helpful to Counsyl in these efforts. Among other introductions coming out of this call, we will connect Counsyl with the largest pediatric network in China and largest government approved cancer treatment centers, with whom we met during our Bus Dev trip to Beijing earlier this year. 
> 
> 5. Board update: We have introduced Ramji to RSTP LP, Bob Cohn. We are considering appointing Bob as the RSTP outside board member. Ramji and the founding team have huge respect for Bob given his background as the founder/CEO of Octel and having commercialized voicemail and build a multi-billion company before selling it to Lucent and becoming a Sequoia partner. Bob has expressed a willingness to join the board although he is generally not taking board seats these days as he manages his family office. Bob and Ramji have lunch on the calendar on 6/6.
> 
> Let's discuss at our partner meeting tomorrow.
> 
> Best,
> 
> John
> 
> John DeLoche
> Co-founder and Managing Director
> Rosemont Seneca Technology Partners
> 333 Bush Street, 21st Floor
> San Francisco, CA 94104
> office: 415 767 1288
> mobile: 415 793 7070 
> 
> This email communication is privileged and confidential and is intended only for the individuals or entities named above. Any unauthorized dissemination of any of the contents of this email is strictly prohibited. If you are not the intended recipient, please do not read, copy, use or disclose to others the contents of this communication. Please notify the sender that you have received this e-mail in error and then delete the e-mail.